| News
ChemAxon establishes subsidiary in Basel
06.11.2020
ChemAxon develops software for application in the chemicals and biopharma industries. Now, the Hungarian company has established a subsidiary in Basel. The customer base and economic conditions were cited as reasons for the choice of location.

The Hungarian company ChemAxon has established the ChemAxon GmbH subsidiary in Basel. The software company chose Basel on account of the connection to customers in the chemicals and biopharma industries as well as the economic conditions. In setting up the new location, it was supported by Basel Area Business & Innovation, the investment and innovation promotion agency (read more about starting a business in Switzerland).
“During the evaluation process and after the incorporation period I was really impressed with all the support and help ChemAxon and I received from BaselArea Business & Innovation,” explains Annamaria Kovacs, the Basel-based representative of ChemAxon.
With headquarters in Budapest, ChemAxon also has offices in the USA, Prague and Asia. Worldwide, ChemAxon has 150 employees. The company’s software products help to accelerate and enhance scientific discovery and collaboration. The solutions are tailored to the requirements of customers in the chemicals and biopharma sectors.
Share this article
Sign up to receive our newsletter in your inbox.
You may also be interested in
KUORI developing biodegradable plastics
The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...
Read MoreCell and gene therapies gain momentum in Basel
Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...
Read MoreBLKB expanding support for startups
BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...
Read MoreCombatting the rise of antimicrobial resistance
Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...
Read MoreAMR Action Fund invests in new antibiotics developed by BioVersys
The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...
Read MoreInvestors give Resistell 8.5 million Swiss francs
Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...
Read More